TScan’s Amgen Agreement Ends as It Redirects Resources to Solid Tumor Therapies
Key Facts
The termination of the collaboration agreement between TScan Therapeutics and Amgen took effect on November 10, 2026, according to a company filing with the U.S. Securities and Exchange Commission. The move followed TScan’s decision in September to direct resources to its solid tumor therapy program using engineered TCR-T cells in vivo. The company announced the reorganization on September 2 as part of a shift in its research and operating priorities. The decision included halting enrollment of new patients in the Phase 3 ALLOHA-2 trial while continuing to follow enrolled patients. The development combines the end of an existing collaboration with the company’s shift to its new solid tumor program.
TScan said the agreement termination would become effective 90 days after delivery of the termination notice and set November 10, 2026, as the effective date. The available filing did not state the agreement’s financial value or a specific financial impact from its termination. In September, the company disclosed its intention to explore partnerships for its hematology and autoimmune disease programs. It also said it would continue to follow patients enrolled in the ALLOHA-2 study. The company set out later updates on data from groups of participants, keeping these programs on its clinical disclosure schedule.
In its solid tumor program, TScan said the first candidates target PRAME and MAGE-A4 and have moved into preparatory studies for IND submissions. The company said it expects to publish preclinical data in the first quarter of 2027. It is also targeting its first IND submission in the third quarter of 2027, followed by the start of Phase 1 in the fourth quarter of the same year. These dates describe a sequence beginning with preclinical data, followed by an application to begin trials and then a move to a human study. These milestones remain timeline targets announced by the company as part of its program plan.
The company said its strategy will begin with one candidate therapy at a time, with the aim of moving later to multi-target therapies. It linked this approach to the challenges of custom manufacturing, treatment delays and the need for lymphodepletion. The company said the program’s design aims to address these difficulties by developing the therapy incrementally, from a single candidate to a multi-target approach. This provides a framework for developing the solid tumor program, alongside preparatory work on the PRAME and MAGE-A4 candidates. The available disclosures did not report human clinical results for either candidate.
On resources, TScan estimated that the reorganization would generate $55 million in cumulative cost savings through the end of 2027. The decision included a workforce reduction of about 75%, according to the September 2 statement. The company said its cash and cash equivalents and marketable securities available on June 30, 2026, were sufficient to fund planned operations through the fourth quarter of 2027. These estimates set a stated time horizon for funding the plan, while the expected savings extend through the end of the same year. The statement did not specify the dollar amount of available liquidity in the facts presented here.
For the ALLOHA-2 trial, the company halted enrollment of new patients in the treatment arm of the Phase 3 study of TSC-101 because of limited capital, while continuing to follow enrolled participants. 7 patients had enrolled in the treatment arm before enrollment was halted. In a separate update, TScan said the 13 patients it is following in Cohort C had achieved complete donor cell matching. The company set the fourth quarter of 2026 for an update on data for Cohort C patients, and the second quarter of 2027 for data on all patients treated using the commercially ready manufacturing process. In the latest available price in EL7 data, TCRX shares closed at $0.1856 on November 11, 2026.
Second-quarter 2026 figures reflect part of the spending realignment that preceded the announcement of the shift. Collaboration and licensing revenue was $1.051 million, compared with $3.076 million in the same period of 2025. Research and development expenses fell to $23.402 million from $32.634 million a year earlier. The company also disclosed on September 2 that it had received a Nasdaq notice for failing to meet the minimum bid price requirement, and said it would consider options to regain compliance without guaranteeing success. The Cohort C data dates and data for patients treated using the commercial manufacturing process, alongside development stages for the solid tumor candidates, remain the main announced milestones through 2027.